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ABSTRACT 
Single gene disorders of the autophagy pathway are an emerging, novel and diverse 
group of multisystem diseases in children. Clinically, these disorders prominently 
affect the central nervous system at various stages of development, leading to brain 
malformations, developmental delay, intellectual disability, epilepsy, movement 
disorders, and neurodegeneration, among others. Frequent early and severe 
involvement of the central nervous system puts the paediatric neurologist, 
neurogeneticist, and neurometabolic specialist at the forefront of recognizing and 
treating these rare conditions. On a molecular level, mutations in key autophagy 
genes map to different stages of this highly conserved pathway and thus lead to 
impairment in isolation membrane (or phagophore) and autophagosome formation, 
maturation, or autophagosome-lysosome fusion. Here we discuss “congenital 
disorders of autophagy” as an emerging subclass of inborn errors of metabolism by 
using the examples of six recently identified monogenic diseases: EPG5-related Vici 
syndrome, beta-propeller protein-associated neurodegeneration due to mutations in 
WDR45, SNX14-associated autosomal-recessive cerebellar ataxia and intellectual 
disability syndrome, and three forms of hereditary spastic paraplegia, SPG11, 
SPG15 and SPG49 caused by SPG11, ZFYVE26 and TECPR2 mutations, 
respectively. We also highlight associations between defective autophagy and other 
inborn errors of metabolism such as lysosomal storage diseases and 
neurodevelopmental diseases associated with the mTOR pathway, which may be 
included in the wider spectrum of autophagy-related diseases from a 
pathobiological point of view. By exploring these emerging themes in disease 
pathogenesis and underlying pathophysiological mechanisms, we discuss how 
congenital disorders of autophagy inform our understanding of the importance of 
this fascinating cellular pathway for central nervous system biology and disease. 
Finally, we review the concept of modulating autophagy as a therapeutic target and 
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argue that congenital disorders of autophagy provide a unique genetic perspective 
on the possibilities and challenges of pathway-specific drug development.  
 
KEY WORDS: Autophagy, inborn errors of metabolism, mammalian target of 
rapamycin (mTOR), neurodevelopment, neurodegeneration 
 
ABBREVIATIONS: AMPK (AMP-activated protein kinase), AR-CAID (autosomal-
recessive cerebellar ataxia and intellectual disability), ATG (autophagy-related 
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(coordinated lysosomal expression and regulation), CNS (central nervous system), 
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(lysosomal storage disease), mTOR (mammalian target of rapamycin), mTORC1 
(mammalian target of rapamycin complex 1), NBIA (neurodegeneration with brain 
iron accumulation), NP-C (Niemann–Pick disease, type C), SENDA (static 
encephalopathy of childhood with neurodegeneration in adulthood), SPG (spastic 
paraplegia gene), TFEB (transcription factor EB), TSC (tuberous sclerosis complex). 
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INTRODUCTION 
Inborn errors of metabolism comprise a large group of single gene disorders 
that affect various aspects of cellular metabolism. Based on the specific pathway 
involved, such conditions can be categorized as disorders of carbohydrate 
metabolism, amino or organic acid metabolism, fatty acid oxidation and 
mitochondrial metabolism, lysosomal diseases, peroxisomal disorders, and others. 
While these conditions are traditionally considered “enzymopathies” due to the 
interruption of specific pathways with resulting accumulation of toxic or interfering 
intermediate products and/or reduced ability to synthesize an essential metabolite, 
the recent introduction of next-generation sequencing into diagnostics has resulted 
in the identification and characterization of novel inborn errors of metabolism. 
One such cellular pathway for inborn errors of metabolism that has emerged 
in recent years is the autophagy pathway, with a number of genetic defects leading 
to inherited multisystem diseases with prominent nervous system involvement. The 
prominent involvement of the CNS, peripheral nerves, and skeletal muscles, often in 
the same patient, puts neurologists and neurogeneticists at the forefront for 
diagnosing and treating “congenital disorders of autophagy”. Putative single gene 
disorders of the autophagy pathway provide a “genetic window” into the role of 
autophagy in humans and will inform our understanding of this fascinating pathway 
and its implications for neurobiology and disease. The latter is particularly important, 
given that dysregulated autophagy has been implicated in many other inherited and 
sporadic diseases, including neurodegenerative and neurodevelopmental diseases 
(Pan et al., 2008a, Ebrahimi-Fakhari et al., 2012, Nixon, 2013, Ebrahimi-Fakhari et 
al., 2014, Ebrahimi-Fakhari and Sahin, 2015), myopathies (Ravenscroft et al., 2015),  
cardiovascular diseases (Lavandero et al., 2013), cancer (Galluzzi et al., 2015), 
infectious diseases (Huang and Brumell, 2014), and metabolic diseases (Christian et 
al., 2013), all of which also affect the CNS.  
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We herein discuss “congenital disorders of autophagy” as an emerging 
subclass of inborn errors of metabolism by using the examples of six monogenic 
diseases of autophagy that affect the brain (Table 1). We also highlight associations 
between defective autophagy and other inborn errors of metabolism such as 
lysosomal storage diseases and neurodevelopmental diseases such as those 
associated with the mTOR pathway. 
 
THE AUTOPHAGY PATHWAY  
Autophagy (Greek for “self-eating”) is the umbrella term for essential 
intracellular pathways that deliver cytosolic cargo to lysosomes for degradation 
(reviewed in detail in Ravikumar et al., 2010, Klionsky et al., 2011, Kaushik and 
Cuervo, 2012, Feng et al., 2014) (please see Supplementary Table 1 for a glossary of 
autophagy-related molecules and processes). At least three subtypes of autophagy 
have been characterized according to the mechanism of cargo delivery: 
microautophagy, chaperone-mediated autophagy, and macroautophagy (Figure 1). 
Microautophagy employs inward invagination of the lysosomal membrane to deliver 
cytoplasmic cargo directly to the lysosome for degradation. Chaperone-mediated 
autophagy selectively recognizes targeting motifs (KFERQ-like motifs) on cytosolic 
proteins and translocates targeted proteins across the lysosomal membrane with 
the help of chaperone-proteins and the lysosomal adapter protein LAMP-2A. 
Macroautophagy uses the de novo formation of double-membrane vesicles to 
sequester parts of the cytosol containing proteins, lipids, and organelles. The basic 
principles underlying autophagy are highly conserved from yeast to mammals, 
highlighting the fundamental importance of this pathway for cellular homeostasis 
and survival. Beyond the turnover of macromolecules and organelles, recent studies 
have implicated a role for autophagy in related cell functions such as membrane 
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trafficking, regulation of energy metabolism (Efeyan et al., 2015), adaptive immunity 
(Gomes and Dikic, 2014), and cell death (Green and Levine, 2014). 
In this review, we focus on macroautophagy (hereafter referred to as 
autophagy), the “bulk” degradation process that is characterized by the formation of 
double-membrane bound autophagic vesicles that undergo a dynamic stepwise 
maturation process: initiation, nucleation of an isolation membrane, elongation of 
evolving vesicles, closure, maturation, and finally fusion with late endosomes or 
lysosomes (Figure 1). The unique double-membrane autophagic vesicle is named 
the autophagosome, while the fusion product of autophagosomes and lysosomes is 
referred to as the autolysosome. Although autophagy has been generally thought of 
as a non-specific degradation pathway, several specific forms of autophagy have 
been identified in recent years. Examples of specific forms of autophagy include the 
selective removal of damaged mitochondria (or “mitophagy”) (Ashrafi and Schwarz, 
2013), peroxisomes (or “pexophagy”) (Oku and Sakai, 2010), ribosomes (or 
“ribophagy”) (Suzuki, 2013), aberrant protein aggregates (or “aggrephagy”) 
(Yamamoto and Simonsen, 2011), and lipid droplets (or “lipophagy”) (Liu and Czaja, 
2013). Posttranslational modifications such as ubiquitination or phosphorylation are 
critical for recruiting and tailoring the autophagy machinery to each specific cargo 
(Okamoto, 2014) and thus might serve as a target for developing therapeutic 
approaches. Ubiquitination seems to be particularly important to label cargo for 
autophagy, and a number of autophagy receptors with an ubiquitin-binding domain 
(such as p62/SQSTM1, NBR1, NDP52 or optineurin) have been identified, adding a 
level of plasticity and precision to the autophagy machinery (Stolz et al., 2014). 
p62/SQSTM1 is of particular interest because it is not only an important adapter 
protein for ubiquitinated cargo (Wurzer et al., 2015), but also a substrate for 
autophagic degradation (Bjorkoy et al., 2005, Komatsu et al., 2007a). Cells deficient 
	 8	
in autophagy therefore often accumulate protein aggregates that contain p62, 
making this a widely used assay to detect autophagy deficits (Klionsky et al., 2012). 
Autophagy is constitutively active to some extent in all cells at any given time 
in order to maintain a homeostatic balance between catabolic and anabolic 
processes. To dynamically adjust autophagic activity to the intracellular metabolic 
state and the extracellular environment, numerous signalling pathways converge to 
regulate autophagy initiation (Figure 2), many of these via mTORC1 (mammalian 
target of rapamycin complex 1) (Lipton and Sahin, 2014) or AMPK (AMP-activated 
protein kinase) (Alers et al., 2012). Maintenance of baseline autophagic flux is 
essential to neurons, skeletal and cardiac muscle. This probably explains the 
increased vulnerability of these tissues to deficits in autophagy and may account for 
the prominent neurological and neuromuscular manifestations in primary disorders 
of autophagy. Specific differences in autophagy regulation and baseline autophagic 
flux in highly differentiated, post-mitotic cells such as neurons remain to be explored 
in detail, and might help to explain the preferential degeneration of specific neuronal 
subtypes such as cerebellar Purkinje cells or long-projecting cortical neurons that 
form projecting or commissural connections. On a similar note, while the role of 
autophagy in neuronal physiology is increasingly appreciated, the contribution of 
defective glial autophagy to neurodegenerative phenotypes in mice (Hara et al., 
2006, Komatsu et al., 2006, Komatsu et al., 2007b, Nishiyama et al., 2007) and 
humans (see below) with defective autophagy remains relatively unexplored. 
Following pioneering work in yeast, many proteins and mechanisms in 
mammalian autophagy have been uncovered. Multiple autophagy-related proteins 
(ATG) coordinate the different steps of autophagosome formation and turnover 
(Figure 2, please see Supplementary Table 1 for a glossary of autophagy-related 
molecules and processes discussed here). The induction step in the autophagy 
cascade is critically determined by the phosphorylation status of the Ulk1-Atg13-
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FIP200 complex, which drives the nucleation of the isolation membrane (Wong et 
al., 2013) (Figure 2). Under normal nutrient conditions, active mTORC1 
phosphorylates Ulk1 (unc-51-like kinase 1) and Atg13 to repress ULK1 kinase 
activity, thereby inhibiting autophagy (Ganley et al., 2009, Hosokawa et al., 2009, 
Jung et al., 2009, Kim et al., 2011). On the other hand, cell stress induced by 
starvation, amino acid deprivation, or growth factor withdrawal inhibits mTORC1 
activity, leading to autophagy induction (Wong et al., 2013).  
AMPK, the second kinase at the heart of autophagy regulation, is a major 
positive regulator of autophagy under stress conditions. Under conditions of low 
intracellular energy (when the ration of AMP to ATP is high), activated AMPK 
induces autophagy both by phosphorylating Ulk1 (at a different site than mTORC1) 
and by inhibiting mTORC1 (Egan et al., 2011, Kim et al., 2011, Di Nardo et al., 2014). 
Both AMPK and mTOR also control cell growth and metabolism, thereby coupling 
these processes to autophagy. 
In the next step of the autophagic cascade, formation of an isolation 
membrane is initiated by a second protein complex, the Beclin1-Atg14L-Vps34 
kinase complex, which enriches the initiation site with phosphatidylinositol-3-
phosphate to recruit interacting regulatory proteins such as Atg9 (Funderburk et al., 
2010) (Figure 2). Atg9 serves as an important adapter molecule that recruits 
membranes and lipids to expand the isolation membrane (Mari et al., 2010, Orsi et 
al., 2012, Yamamoto et al., 2012). On a regulatory level, phosphorylation of Beclin-1 
by Akt inhibits autophagy (Wang et al., 2012b), while phosphorylation at a different 
residue by AMPK or ULK1 promotes its integration into the Beclin1-Atg14L-Vps34 
kinase complex and initiates autophagy (Kim et al., 2013, Russell et al., 2013). 
Likewise, phosphorylation of Atg9 by ULK1 is required for the efficient recruitment 
of additional factors to the formation site and subsequent expansion of the isolation 
membrane (Papinski et al., 2014). 
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The precise subcellular location where the isolation membrane is formed 
remains controversial, with the endoplasmic reticulum, Golgi complex, plasma 
membrane, recycling endosomes, and mitochondrial membrane being putative 
candidates (Lamb et al., 2013). It seems likely that membranes are derived from 
multiple sources and perhaps in a cell type- or even location-specific manner, e.g. it 
is conceivable that the source of autophagic membranes might be different in distal 
neurites compared to the cell body. Elongation of evolving autophagosomes 
requires two ubiquitin-like conjugation systems: the Atg5-Atg12-Atg16L1 and the 
LC3 (microtubule-associated protein light chain 3 or Atg8) - 
phosphatidylethanolamine conjugation system (Mizushima et al., 2011) (Figure 2); 
the former functions as an E3 ligase that mediates the lipidation of LC3, whereas 
lipidated LC3 and its family members GATE16 and GABARAP are coupled to the 
autophagosomal membrane where they support its elongation and closure. The 
lipidated form of LC3, LC3-II, is of particular interest since it localizes to the inner 
and outer autophagosomal membrane, making this protein a widely used marker to 
identify and quantify autophagosome formation and turnover (Klionsky et al., 2012). 
Fusion with lysosomes, the final step in the lifecycle of autophagosomes, 
often occurs in the perinuclear region, where the bulk of lysosomes usually reside. 
Autophagic vesicles, however, almost certainly form everywhere in the cell and thus 
have to be shipped towards the perinuclear region by dynein-dependent retrograde 
transportation on microtubules. This process is particularly important for neurons 
with their long processes (Maday et al., 2012, Cheng et al., 2015). Local autophagic 
degradation, for example of damaged mitochondria (Ashrafi et al., 2014), might be 
another important contributor to homeostasis in remote cellular regions such as 
distal axons, where most of the axonal autophagosomes form (Maday and Holzbaur, 
2014). Lysosomal enzymes efficiently degrade the sequestered cargo, and the basic 
building blocks are recycled back to the cytosol for reuse. After cargo degradation, 
	 11	
lysosomal components are also retrieved from autolysosomes to replenish the 
lysosomal pool (Yu et al., 2010). 
Not surprisingly, lysosomal metabolism is intimately coupled to autophagy 
regulation. This is achieved on the transcriptional level through a recently described 
pathway that involves the master regulator of both lysosomal and autophagic 
vesicle biogenesis, the basic helix-loop-helix leucine-zipper transcription factor EB 
(TFEB). TFEB regulates the expression of the coordinated lysosomal expression and 
regulation (CLEAR) network of genes involved in lysosomal biogenesis and 
autophagy (Sardiello et al., 2009, Palmieri et al., 2011, Settembre et al., 2011). 
Interestingly, mTORC1 associates and phosphorylates TFEB at the lysosomal 
membrane under conditions of nutrient sufficiency and thus prevents its 
translocation to the nucleus. In response to cellular energy depletion, however, 
mTORC1-dependent phosphorylation of TFEB is impaired, triggering the 
transcription of genes that encode proteins required for autophagosome formation 
and autophagic flux (Martina et al., 2012, Roczniak-Ferguson et al., 2012). Given its 
central role in regulating the autophagy-lysosomal pathway, TFEB has gained 
significant attention as a potential therapeutic target for diseases where defective 
autophagy and/or lysosomal dysfunction have been implicated, such as hepatic a1-
antitrypsin deficiency (Pastore et al., 2013), Pompe disease (Spampanato et al., 
2013), Parkinson’s disease (Decressac et al., 2013) or Huntington’s disease 
(Tsunemi et al., 2012). 
 
CONGENITAL DISORDERS OF AUTOPHAGY 
The emergence of rapid and more widely available next-generation DNA 
sequencing technology has led to the identification of the genetic basis of many rare 
diseases, including inborn errors of metabolism. Single gene disorders affecting the 
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autophagy pathway are increasingly identified, and genetic variants in autophagy 
genes are found to contribute to a number of major diseases. Here we discuss six 
“congenital disorders of autophagy” (Table 1) that predominantly affect the brain 
and argue for a novel subclass of inborn errors of metabolism. 
 
VICI SYNDROME – EPG5 MUTATIONS 
First described in 1988 by Dionisi-Vici et al., Vici syndrome (OMIM #242840) 
is a rare autosomal recessive multisystem disease with about 50 published cases to 
date (Byrne et al., joint submission and Dionisi Vici et al., 1988, del Campo et al., 
1999, Chiyonobu et al., 2002, Miyata et al., 2007, Al-Owain et al., 2010, McClelland 
et al., 2010, Rogers et al., 2011, Finocchi et al., 2012, Ozkale et al., 2012, Said et al., 
2012, Cullup et al., 2013, Cullup et al., 2014, Ehmke et al., 2014, Filloux et al., 2014, 
Tasdemir et al., 2015). Vici syndrome is classically characterized by a set of five 
cardinal features that include agenesis of the corpus callosum, bilateral cataracts, 
hypertrophic and/or dilated cardiomyopathy, combined immunodeficiency, and skin, 
hair and retinal hypopigmentation (Figure 3). These five manifestations in addition to 
three features recently identified to occur in the majority of Vici patients, namely 
acquired microcephaly, failure to thrive and profound developmental delay, allow a 
clinical diagnosis that is confirmed by a positive genetic test with a specificity and 
sensitivity of greater than 90% (Byrne et al., joint submission). Congenital midline 
defects such as a cleft lip or palate, thymic aplasia or congenital deficiency of the 
thymus, and hypospadia may also occur but are less frequent. Additional general 
findings include facial dysmorphism, dysphagia, recurrent pulmonary and 
mucocutaneous infections secondary to immunodeficiency, and neonatal-onset 
hypotonia secondary to myopathy. Chronic anaemia, renal tubular acidosis, liver 
dysfunction, and lung hypoplasia have also been described in a few cases (Figure 
3).  
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The neurological phenotype is broad and, in addition to the prominent 
feature of agenesis of the corpus callosum (often with colpocephaly), which occurs 
in virtually all patients, involves other brain malformations such as non-
lissencephalic cortical or cerebellar vermis dysplasia, pontine hypoplasia, 
abnormalities of the septum pellucidum, abnormal T2 signal diffusely in the thalami, 
and myelination defects (Table 1 & Figure 3). Of these secondary features, reduced 
white matter bulk and under-opercularisation of the Sylvian fissures are found in the 
majority of patients. Post-mortem examination of a single case confirmed agenesis 
of the corpus callosum as well as prominent hypoplasia of the pons and cortico-
spinal tracts (Byrne et al., joint submission). Neurological sequelae are manifold and 
include progressive postnatal microcephaly, profound developmental delay and 
intellectual disability, motor impairment, nystagmus, sensorineuronal deafness, and 
seizures (Table 1 & Figure 3). In infancy, the latter frequently evolve into epileptic 
encephalopathy that is often refractory to treatment. Interestingly, the reported loss 
of previously acquired skills as well as the occurrence of progressive microcephaly 
in Vici patients who survive the neonatal period, suggest a neurodegenerative 
component in addition to the prominent neurodevelopmental defects. This notion is 
corroborated by a neurodegenerative phenotype in Epg5-deficient Drosophila 
melanogaster (Byrne et al., joint submission) and transgenic mice (Zhao et al., 
2013a) as discussed below. The disease is usually fatal in infancy or early childhood 
with recurrent, severe infections and/or progressive heart failure likely being the 
main cause of mortality. 
Using whole-exome sequencing in affected individuals, Cullup et al. 
identified recessive mutations in the EPG5 gene on chromosome 18q12.3 as the 
genetic cause of Vici syndrome (Cullup et al., 2013). EPG5 consists of 44 exons 
encoding a protein of 2579 amino acids at maximum. The mutations identified so far 
map to almost the entire gene with no clear mutational hotspot (Byrne et al., joint 
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submission). Most mutations are predicted to lead to a truncated protein product, 
thus favouring a loss-of-function mechanism. EPG5 is the human homolog of the 
metazoan-specific autophagy gene Epg5 (ectopic P-granule autophagy protein 5), 
which encodes the key regulatory autophagy protein Epg5. Like many autophagy-
related genes, Epg5 first emerged in a Caenorhabditis elegans based genetic 
screening for modifiers of autophagic substrate degradation. Mutant Epg5 in C. 
elegans as well as a gene knockdown in mammalian cells was found to result in the 
accumulation of dysfunctional non-degenerative autolysosomes, arguing that Epg5 
is critically involved in the late stages of the autophagy cascade such as 
autophagosome-lysosome fusion or proteolysis within autolysosomes (Tian et al., 
2010, Zhao et al., 2013a). 
Further delineating the role of Epg5, characterization of autophagy in skeletal 
muscle tissue and fibroblasts from Vici patients revealed an accumulation of LC3-
positive autophagic vesicles, and of the autophagy linker-proteins NBR1 and p62. 
This suggests a block in autophagic flux, a finding further corroborated by the 
accumulation of K63-polyubiquitinated proteins, which are usually targeted for 
autophagic degradation. Evidence for a block at the late stages of autophagy, 
namely during autophagosome-lysosome fusion, was provided by showing a 
reduction in the co-localization of both organelles (Cullup et al., 2013). In retrospect, 
these findings are consistent with earlier studies in available muscle biopsies from 
Vici patients that found abundant vacuoles and dense bodies suggesting a 
lysosomal origin (Al-Owain et al., 2010, McClelland et al., 2010, Cullup et al., 2013).  
In summary, Epg5 deficiency in Vici syndrome leads to a critical impairment 
of the late stages of the autophagy pathway (Table 1 & Figure 2). Global reduction in 
autophagic flux leads to impaired development and function in a multitude of tissues 
and thus to a multisystem disease (Figure 3). Recurrent infections are a significant 
source of morbidity and mortality in Vici syndrome. This might be secondary to the 
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fact that defective autophagy impairs immunity and the clearance of intracellular 
pathogens in particular, as this has been recently found to critically depend on intact 
autophagy (Jo et al., 2013). Despite the convincing role for EPG5 mutations in 
human cases, Epg5 knockout mice do not fully recapitulate the phenotype found in 
Vici syndrome and interestingly resemble instead key neuropathological features of 
the neurodegenerative disease amyotrophic lateral sclerosis (Zhao et al., 2013a). 
Neurodegeneration mainly occurs in cortical pyramidal neurons and motor neurons 
of the spinal cord and is accompanied by accumulation of p62-positive and 
ubiquitinated protein aggregates. Not surprisingly, knockout mice display 
progressive motor deficits and die around 12 months of age. Muscle atrophy, 
fibrillations and sharp waves on electromyography indicate active denervation. 
Interestingly, in addition to the degenerative changes secondary to denervation, 
glycogen accumulation is found in skeletal muscle of Epg5 deficient mice arguing 
for a “storage disease phenotype” similar to glycogen accumulation observed in 
muscle and other tissues from Vici syndrome patients (Al-Owain et al., 2010, 
McClelland et al., 2010, Cullup et al., 2013). Although no overt developmental brain 
malformations were discovered, Epg5 deficient mice were consistently found to 
have a reduced thickness of the corpus callosum with a partial or complete 
agenesis in a few knockout animals (Zhao et al., 2013b). Thus, while Epg5 knockout 
mice show some phenotypic similarities to Vici syndrome patients including corpus 
callosum dysgenesis and myopathy, core clinical features, however, are not 
recapitulated. Nevertheless, Vici syndrome, a multisystem disease in humans, is an 
important example for the concept of “congenital disorders of autophagy” as it 
highlights the consequences of dysfunctional autophagy for organ development and 
the complex role of autophagy in CNS development. 
 
BETA-PROPELLER PROTEIN-ASSOCIATED NEURODEGENERATION (BPAN) – 
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WDR45 MUTATIONS 
Neurodegeneration with brain iron accumulation (NBIA) is a clinically and 
genetically heterogeneous group of single gene disorders characterized by 
dysregulation of iron metabolism leading to iron deposits in the basal ganglia, 
particularly in the globus pallidus and substantia nigra (Horvath, 2013, Meyer et al., 
2015). A recently identified subtype within this group is beta-propeller protein-
associated neurodegeneration (BPAN), a disease that had been previously 
summarized under the term Static Encephalopathy of Childhood with 
Neurodegeneration in Adulthood (SENDA) syndrome, based on its distinct pattern of 
clinical and MRI findings and its characteristic natural history (Figure 4). BPAN 
accounts for approximately 1-2 % of all NBIA cases and is the only form of the 
disease with an X-linked dominant inheritance pattern, although thus far only 
patients carrying de novo mutations have been reported (Haack et al., 2012, Saitsu 
et al., 2013, Nishioka et al., 2015).  
Clinically, BPAN is a biphasic disease that begins with global developmental 
delay in infancy or early childhood (Table 1 & Figure 4) (Hayflick et al., 2013, 
Nishioka et al., 2015). Seizures of various types including generalized tonic-clonic 
but also focal, absence, atonic or myoclonic seizures are frequent initial 
presentations, often in the context of a febrile illness. Spastic paraparesis is another 
commonly reported early finding. Symptoms remain relatively static until the second 
phase of the disease suddenly begins in adolescence or early adulthood with 
progressive cognitive decline, dementia, dystonia, and Parkinsonism dominating the 
clinical picture. The latter mainly consists of bradykinesia, rigidity and postural 
instability while tremor is not commonly seen. In a number of cases, these 
symptoms have responded to levodopa (Hayflick et al., 2013). Seizures, too, usually 
progress in the adult phase of the disease. Sleep abnormalities, neuropsychiatric 
symptoms within the autistic and affective spectrum, eye movement abnormalities, 
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optic nerve atrophy, sensorineural hearing loss and Rett-like hand stereotypies have 
also been reported in a subset of patients (Hayflick et al., 2013, Ohba et al., 2014, 
Rathore et al., 2014, Verhoeven et al., 2014). Distinctive MRI changes allow a 
diagnosis in many cases (Kruer et al., 2012): Iron accumulation is detectable on 
regular T2 sequences in the substantia nigra even at an early disease stage, while 
detecting iron deposits in the globus pallidum requires other techniques such as 
gradient-echo or T2*-weighted sequences. Hyperintensity on T1-weighted axial 
images with a central band of hypointense signal has been reported as a 
pathognomonic feature of BPAN (Kruer et al., 2012, Ichinose et al., 2014, Ozawa et 
al., 2014). Cerebral atrophy, or less commonly cerebellar atrophy, and basal ganglia 
calcification (Van Goethem et al., 2014) can also be seen. Post-mortem examination 
of two adult cases of BPAN revealed extensive and widespread accumulation of 
hyperphosphorylated tau protein in the form of neurofibrillary tangles, arguing that 
BPAN shares neuropathological features with classic degenerative tauopathies such 
as Alzheimer’s disease (Hayflick et al., 2013, Paudel et al., 2015). BPAN is inevitably 
fatal with current therapeutic strategies being targeted at symptomatic relief of 
Parkinsonian features, dystonia, and seizures.  
Using exome sequencing, two independent groups recently uncovered 
mutations in the WDR45 gene as the genetic cause of BPAN (Haack et al., 2012, 
Saitsu et al., 2013). WDR45, also known as WIPI4, is located on the X-chromosome 
and is one of the four mammalian homologs of the core autophagy gene Epg6 in C. 
elegans (Proikas-Cezanne et al., 2004, Lu et al., 2011). WDR45 encodes a WD 
repeat protein, a superfamily of proteins that is characterized by repeating units with 
a conserved core of approximately 40 amino acids that terminate with tryptophan-
aspartic acid (WD) residues. WD40 proteins have a highly symmetrical beta-
propeller tertiary structure that enables them to regulate the assembly of 
multiprotein complexes by providing a stable anchoring platform for simultaneous 
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and reversible protein-protein interactions (Stirnimann et al., 2010). Based on these 
properties, WD-repeat proteins are key components of many essential biological 
functions and pathways, including autophagy, signal transduction pathways, 
transcriptional regulation, cell cycle control, apoptosis, and vesicular trafficking 
(Stirnimann et al., 2010).  
WDR45, the WD-repeat protein mutated in BPAN, interacts with autophagy 
proteins Atg2 and Atg9 to regulate key steps during autophagosome formation and 
elongation (Behrends et al., 2010, Lu et al., 2011). Hence, depletion of WDR45 in 
mammalian cells leads to the accumulation of autophagosomes and early 
autophagic vesicles (Behrends et al., 2010, Lu et al., 2011). Investigating the effect 
of WDR45 mutations in lymphoblast cell lines derived from BPAN patients, Saitsu et 
al. found that levels of WDR45 protein were strongly diminished, suggesting that the 
mutant protein is structurally unstable and undergoes rapid degradation (Saitsu et 
al., 2013). Subsequently, autophagic flux is impaired, leading to an accumulation of 
abnormal and immature autophagic vacuoles. The latter was confirmed by showing 
that accumulating abnormal autophagosome precursors stain for both Atg9A and 
LC3, indicating improper autophagosome formation, since, under normal 
conditions, Atg9A only transiently associates with the autophagosome formation 
site and is absent from mature LC3-positive autophagosomes (Orsi et al., 2012). In 
summary, findings in cells from BPAN patients indicate that autophagy is perturbed 
at an early stage (Table 1 & Figure 2), suggesting that autophagy dysfunction might 
account for the neurological sequelae of the disease. Interestingly, although BPAN 
is clinically thought to primarily affect the brain, WDR45 is expressed in many 
human tissues with the highest expression found in skeletal muscle (Proikas-
Cezanne et al., 2004). A muscle phenotype, however, remains to be formally 
investigated. The selective degeneration of neuronal populations may be explained 
by cell-type specific differences in autophagy and tolerance to changes in this 
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pathway. Neurons as non-dividing, highly differentiated cells heavily rely on 
intracellular degradation pathways to maintain homeostasis and normal structure 
and function. This is exemplified by brain-specific knockout mice of core autophagy 
genes showing a striking neurodegenerative phenotype similar to that found in 
aging-related neurodegenerative diseases (Hara et al., 2006, Komatsu et al., 2006). 
Since mice globally deficient in autophagy die shortly after birth (Kuma et al., 2004, 
Komatsu et al., 2005), WDR45 mutations in affected human males might be 
inevitably lethal at an early stage. Recently reported conditional CNS-specific 
WDR45 knockout mice (Nes-WDR45fl/Y) show axonal pathology with swollen axons 
and accumulation of autophagy substrates p62 and ubiquitin. Although neither 
neurodegeneration nor iron deposition are prominent phenotypes, Nes-WDR45fl/Y 
mice, at the behavioural level, exhibit subtle motor coordination deficits and poor 
learning and memory, suggesting deficits in neuronal circuit formation or 
neurotransmission (Zhao et al., 2015). Another interesting lead into the pathogenesis 
of BPAN comes from the recent appreciation of the role of autophagy in iron 
metabolism. The bioavailability of intracellular iron is critically controlled through the 
delivery of ferritin to autophagosomes and lysosomes for degradation 
(ferritinophagy), allowing release of iron into the cytoplasm (Kidane et al., 2006, 
Asano et al., 2011, Mancias et al., 2014). Hence, deficits in ferritinophagy could 
disturb iron homeostasis, potentially contributing to the iron storage phenotype seen 
in NBIA that seems to confer selectivity for vulnerable brain regions.  
In summary, BPAN, the second discussed congenital disorder of autophagy, 
is of particular importance as this disease, for the first time, confirms that genetic 
deficits in the autophagy pathway are indeed associated with early-onset 
neurodegeneration in humans (Saitsu et al., 2013). This further supports a role for 
autophagy in the pathogenesis of an expanding list of sporadic aging-related 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, 
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Huntington’s disease, and others (Ebrahimi-Fakhari et al., 2012, Nixon, 2013) and 
may provide novel insights into the role of autophagy in iron metabolism. 
 
SNX14-ASSOCIATED AUTOSOMAL-RECESSIVE CEREBELLAR ATAXIA AND 
INTELLECTUAL DISABILITY SYNDROME 
The childhood-onset autosomal-recessive cerebellar ataxias are a group of 
heterogeneous inherited diseases characterized by progressive cerebellar atrophy 
and prominent Purkinje cell degeneration. Next-generation sequencing has allowed 
a genetic and molecular resolution of a number of entities and holds great promise 
to facilitate an early diagnosis in many cases (Nemeth et al., 2013, Pyle et al., 2015). 
Recently, two independent groups identified truncating loss-of-function mutations in 
the sorting nexin gene, SNX14, as the cause of a clinically distinct autosomal-
recessive cerebellar ataxia syndrome (Thomas et al., 2014, Akizu et al., 2015). 
Patients with bi-allelic SNX14 mutations present with globally delayed development, 
hypotonia, absent speech, progressive cerebellar atrophy and ataxia, seizures, and 
a storage disease phenotype consisting of coarse facial features, macroglossia, 
hypertrychosis, kyphoscoliosis, sensorineural hearing loss, and 
hepatosplenomegaly in a few cases (Table 1) (Sousa et al., 2014, Thomas et al., 
2014, Akizu et al., 2015). On clinical grounds, these manifestations suggest 
overlapping disease mechanisms with lysosomal storage diseases with prominent 
involvement of the cerebellum such as Niemann-Pick disease type C (NP-C) or Tay-
Sachs disease. Indeed, mutant SNX14 patient fibroblasts contain enlarged 
lysosomes (Thomas et al., 2014, Akizu et al., 2015), providing a rationale to further 
investigate the role of SNX14 in lysosomal turnover. 
SNX14 encodes a protein of the sorting nexin family that contains two 
putative transmembrane domains (Mas et al., 2014). Through the RGS (regulator of 
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G protein signalling) domain, SNX14 attenuates Gas-coupled G protein-coupled 
receptor signalling. Through its PX (phox homology) domain SNX14 binds 
membrane phosphatidylinositol residues and is involved in intracellular trafficking. 
Phospholipids on membranes of different organelles provide a platform for recruiting 
factors that mediate membrane turnover and fusion. With regards to the autophagy 
pathway, this is important for key membrane fusion events such as the fusion of 
phosphatidylinositol 3-phosphate coated autophagosomes with phosphatidylinositol 
(3,5)-bisphosphate carrying lysosomes (Dall'Armi et al., 2013). The importance of 
phospholipids for autophagy is exemplified by recent studies that show key 
regulatory functions in the regulation of canonical (Burman and Ktistakis, 2010) and 
non-canonical autophagy (Vicinanza et al., 2015). In addition, cardiolipins, a subtype 
of phospholipids localized to the inner mitochondrial membrane, serve as a crucial 
signal for autophagic degradation when exposed on the surface of depolarized 
mitochondria (Chu et al., 2013). Binding to their respective phospholipid signature, 
SNX14 co-localizes with the lysosome and is enriched in autophagosome containing 
cell fractions (Akizu et al., 2015). In induced pluripotent stem cell (iPSC)-derived 
neuronal cells from patients with SNX14 mutations, lysosomes are increased in size 
and autophagosome clearance is impaired (Akizu et al., 2015). This pattern closely 
resembles findings in certain lysosomal storage diseases (Ebrahimi-Fakhari et al., 
2014). Knockdown of SNX14 in a zebrafish model confirmed these observations and 
linked them to progressive Purkinje cell loss, suggesting neuronal cell death 
secondary to impaired autophagy (Akizu et al., 2015). Purkinje cells are exquisitely 
sensitive to autophagy impairment and perturbations of lysosomal metabolism (Hara 
et al., 2006, Komatsu et al., 2006), which may be attributable to their size, high 
metabolic activity, and complex dendritic architecture. Not surprisingly, post-
mortem neuropathological assessment showed a near complete absence of 
Purkinje cells in an affected individual with bi-allelic SNX14 mutations (Akizu et al., 
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2015).  
SNX14-associated autosomal-recessive cerebellar ataxia is thus a further 
disease that links autophagy to neurodegeneration and highlights the importance of 
autophagy for Purkinje cell function and survival. Given the emerging links between 
cerebellar circuit dysfunction and syndromic forms of autism-spectrum disorder 
(Tsai et al., 2012), it is interesting to note that the majority of reported patients with 
SNX14 mutations show autistic-like behaviour (Akizu et al., 2015). 
 
HEREDITARY SPASTIC PARAPLEGIA - SPG11 (SPG11), SPG15 (ZFYVE26) AND 
SPG49 (TECPR2) 
Hereditary spastic paraplegia (HSP) is a clinically and genetically 
heterogeneous group of neurodegenerative diseases that occurs at a prevalence of 
about 3-10 cases per 100.000 individuals (Salinas et al., 2008, Blackstone, 2012). All 
forms of HSP share the unifying feature of distal axonal degeneration in the 
corticospinal tracts (Lo Giudice et al., 2014). In some cases, ascending spinal tracts 
such as the gracile fasciculus and the spinocerebellar tracts may also be affected. 
Clinically, degeneration of the corticospinal tracts leads to progressive weakness 
and spasticity of the lower limbs. Additional manifestations in the various forms of 
HSP described to date range from congenital brain abnormalities such as agenesis 
of the corpus callosum or cerebellar dysplasia, to signs of neuronal dysfunction and 
neurodegeneration such as cognitive impairment, ataxia, optic nerve atrophy, 
epilepsy, and peripheral neuropathy (Lo Giudice et al., 2014). Given the unifying 
feature of axonal degeneration of the long tracts, the HSPs serve as a genetically 
tractable model for identifying pathways that ensure axonal function and survival. 
Covering all modes of inheritance, more than 70 disease loci and 50 spastic 
paraplegia genes have been identified to date. These genes map to multiple cellular 
pathways and processes, including endoplasmic reticulum function, vesicle 
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formation, membrane trafficking, mitochondrial function, lipid metabolism, 
myelination, axonal transport and autophagy (Blackstone, 2012, Lo Giudice et al., 
2014, Noreau et al., 2014). Here, we discuss SPG11, SPG15 and SPG49, three 
autosomal recessive forms of HSP characterized by autophagy dysfunction. 
SPG11 (OMIM #604360) and SPG15 (OMIM #270700) are the most prevalent 
forms of autosomal recessive HSP with thin corpus callosum (Goizet et al., 2009, 
Schule et al., 2009, Pensato et al., 2014). The clinical phenotype in SPG11 and 
SPG15 is often indistinguishable (Table 1) and an accurate diagnosis therefore 
requires genetic testing (Schule et al., 2009). Patients with SPG11 or SPG15 often 
present with Kjellin syndrome, in which early-onset spastic paraplegia is 
accompanied by intellectual disability, pigmentary retinopathy, cerebellar 
dysfunction, and distal amyotrophy in the first or second decade of life (Kjellin, 
1959). Parkinsonism is also sometimes observed.  
Following linkage to the SPG11 locus on chromosome 15q (Martinez Murillo 
et al., 1999, Shibasaki et al., 2000), the gene for SPG11, SPG11, and its protein 
product spatacsin were identified (Stevanin et al., 2007, Stevanin et al., 2008). 
For SPG15, Hughes et al. were first to identify the causative gene locus on 
chromosome 14q from two Irish families with autosomal-recessive Kjellin syndrome 
(Hughes et al., 2001) before Hanein et al. pinpointed the causal gene to ZFYVE26, 
which encodes the zinc-finger protein spastizin (Hanein et al., 2008). Over 100 
mutations in SPG11 and more than 20 mutations in ZFYVE26 have been identified in 
patients, the majority of which are truncating, nonsense mutations (Goizet et al., 
2009, Pensato et al., 2014). 
 Spastizin is a 285kDa protein comprising of a zinc finger domain, a FYVE 
domain, and a leucine zipper domain (Hanein et al., 2008). FYVE-domain containing 
proteins bind phosphatidylinositol 3-phosphate, suggesting a likely function of 
spastizin in membrane trafficking (Kutateladze and Overduin, 2001). Spastizin is 
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expressed most abundantly in motor cortex, hippocampus, cerebellum, pons and 
spinal cord, particularly during development (Hanein et al., 2008, Murmu et al., 2011, 
Khundadze et al., 2013). Intracellularly, spastizin has been observed to co-localize 
with a variety of structures and organelles, including endosomes and the 
endoplasmic reticulum and, to a likely lesser extent, microtubules, mitochondria, 
and the nucleus (Hanein et al., 2008, Murmu et al., 2011, Khundadze et al., 2013, 
Vantaggiato et al., 2013). 
Zfyve26 knockout mice develop normally but by 12 months of age acquire a 
spastic and ataxic gait disorder accompanied by neuron loss in the motor cortex 
and the cerebellum, thus recapitulating the clinical phenotype of HSP patients 
(Khundadze et al., 2013). Zebrafish models generated by morpholino-mediated 
knockdown of SPG15 also show motor neuron growth impairment and 
morphological abnormalities (Martin et al., 2012). Interestingly, knockdown of 
SPG11 results in a strikingly similar phenotype (Martin et al., 2012), providing 
genetic evidence that spastizin and spatacsin might act as part of the same 
pathway as previously suggested by physical interaction of the two proteins 
(Slabicki et al., 2010) and overlapping clinical features in SPG15 and SPG11 patients 
(Boukhris et al., 2008, Schule et al., 2009). 
At the cellular level, high-density Lamp1-positive membrane-bound vesicles 
and lipopigment accumulate in neurons of Zfyve26 knockout mice and precede 
neurodegenerative changes (Khundadze et al., 2013). Enlarged lysosomes are 
readily visible in fibroblasts derived from SPG15 patients (Renvoise et al., 2014), 
similarly suggesting deficits in the autophagy-lysosomal and/or endosomal-
lysosomal pathway. Vantaggiato et al. recently provided an important lead by 
identifying an interaction between spastizin and the Beclin 1-UVRAG-Rubicon 
complex of the autophagy pathway (Vantaggiato et al., 2013) (Figure 2). As 
discussed above, Beclin 1 has a multifaceted role in autophagy: in association with 
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Atg14L and Ambra1, the Beclin 1-Vps34-Vps15 class III phosphatidylinositol 3-
kinase complex is involved in autophagosome formation by regulating 
phosphatidylinositol 3-phosphate synthesis; separately, when interacting with 
cofactors UVRAG and Bif-1, Beclin 1-Vps34-Vps15 induces autophagosome 
maturation and endosome fusion. Finally, Rubicon, in complex with UVRAG and 
Beclin 1-Vps34-Vps15, functions as a negative regulator of autophagy (Liang et al., 
2006, Itakura et al., 2008, Matsunaga et al., 2009, Zhong et al., 2009, Kang et al., 
2011). Spastizin interacts with the Beclin 1-UVRAG-Rubicon multiprotein complex 
and is thus involved in autophagosome maturation (Vantaggiato et al., 2013, 
Vantaggiato et al., 2014). Mutations in spastizin disrupt its interaction with Beclin 1 
and inhibit autophagosome maturation, leading to an accumulation of immature 
autophagosomes in fibroblasts and lymphoblasts from SPG15 patients (Vantaggiato 
et al., 2013). RNA-interference-mediated knockdown of spastizin in cultured 
neurons was shown to yield similar results. In addition, reduced colocalization of 
LC3 and Lamp1 was noted in basal and autophagy-promoting conditions, indicating 
a block in autophagosome-lysosome fusion (Vantaggiato et al., 2013). Recently, 
pathogenic alterations of autophagy and lysosomal function in SPG15 have been 
further confirmed by showing that spastizin and the SPG11 protein spatacsin are 
instrumental for the reformation of autophagic lysosomes, a recycling pathway that 
generates new lysosomes (Chang et al., 2014, Varga et al., 2015). This mechanism 
of lysosome biogenesis maintains a pool of lysosomes that are competent to fuse 
with autophagosomes in order to create new autolysosomes (Yu et al., 2010). 
Spastizin forms a complex with spatacsin and is targeted to lysosomes through 
spastizin’s FYVE domain. Loss of either spastizin or spatacsin results in 
accumulation of enlarged autolysosomes, which is reversible by reintroducing wild-
type spastizin. Similarly, accumulation of autophagosomes and depletion of free 
lysosomes is seen, suggesting a block at the autophagic lysosome reformation 
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stage (Chang et al., 2014, Varga et al., 2015). Taken together, disruption of the 
critical steps of autophagosome maturation and lysosomal biogenesis contributes 
to the neurodegeneration seen in SPG15 and related forms of HSP such as SPG11.  
In 2012, Oz-Levi et al. identified a new form of apparently autosomal-
recessive HSP, SPG49 (OMIM #615031), in three Jewish Bukharian families. 
Affected individuals present with distinct dysmorphic features, delayed development 
and muscular hypotonia at around 2 years of age before phenotypically progressing 
to intellectual disability, spastic paraplegia, rigidity, dysarthria and ataxia (Oz-Levi et 
al., 2012). Severe central apnoea and gastrooesophageal reflux disease are 
additional features of the disease. Exome sequencing revealed a single and likely 
causal variant (c.3416delT) in the tectonin β-propeller containing protein 2 (TECPR2) 
gene (also KIAA0329), resulting in a premature stop codon (Oz-Levi et al., 2012). 
The truncated protein resulting from the putative pathogenic c.3416delT mutation 
undergoes rapid degradation, indicating a loss-of-function mechanism. Through 
high-throughput proteomic analysis of the autophagy pathway, TECPR2 has been 
established to be a binding partner of the mammalian Atg8 protein family, including 
LC3, and a probable positive regulator of autophagosome formation (Behrends et 
al., 2010). Using fibroblasts of affected SPG49 patients and siRNA-mediated 
knockdown of TECPR2 in cultured cell lines, loss of TECPR2 was found to result in 
a decreased number of autophagosomes and reduced delivery of LC3 and p62 for 
lysosomal degradation. These results suggest that SPG49 pathology involves a 
significant, though not entirely complete, impairment of the autophagy pathway (Oz-
Levi et al., 2012). Providing insights into the mechanism of defective autophagy in 
SPG49, a recent study showed that TECPR2 is involved in maintaining functional ER 
exit sites, which may serve as scaffolds for the formation of autophagosomes 
(Stadel et al., 2015). 
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AUTOPHAGY IN mTOR-ASSOCIATED NEURODEVELOPMENTAL DISEASES 
 Pathways that monitor nutrient or amino acid supply (mTORC1 pathway) and 
cellular ATP-levels (AMPK pathway) critically control autophagy. A central regulator 
of cellular metabolism, the ubiquitously expressed serine/threonine kinase mTORC1 
facilitates anabolic processes that supply the basic building blocks for cell growth, 
differentiation and proliferation. Not surprisingly, mTORC1 also blocks catabolic 
pathways such as autophagy via transcriptional and post-translational mechanisms. 
Conversely, conditions known to induce autophagy, such as for example starvation 
or growth factor deprivation, effectively reduce mTORC1 activity. Critical targets of 
mTORC1 that mediate its effect on autophagy are TFEB, regulating autophagy at 
the transcriptional level, and the ULK1/2 complex, AMBRA1 and the ATG14L-
associated VPS34 complex, proteins that are involved in the autophagy initiation 
step as discussed above (Figure 2). mTORC1 is important for disorders of 
autophagy for two reasons: firstly, genetic deficits of the mTOR pathway will almost 
certainly provoke changes in autophagy, and therefore “mTORpathies” can be 
regarded as “congenital disorders of autophagy regulation,” and secondly and 
perhaps most importantly, mTORC1 inhibitors, including drugs currently approved 
for a variety of conditions, are clinically available inducers of autophagy. An example 
for an mTOR-associated neurodevelopmental disease with defective autophagy is 
tuberous sclerosis complex (TSC). In this multisystem disease, loss-of function 
mutations in TSC1 or TSC2 lead to a constitutive activation of the mTORC1 
pathway (Lipton and Sahin, 2014, DiMario et al., 2015). Overactive mTORC1 is the 
key pathogenic molecular mechanism in TSC and provides the scientific rationale 
for the use of mTORC1 inhibitors to treat this disease (Julich and Sahin, 2014, 
Ebrahimi-Fakhari and Sahin, 2015). Autophagy deficits in TSC have been implicated 
as contributors to epileptogenesis (McMahon et al., 2012), brain malformations 
(Yasin et al., 2013), tumour formation (Liang et al., 2014), autism, and neurocognitive 
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deficits (Tang et al., 2014) by impacting neuronal metabolism and synaptic 
signalling. Understanding autophagy dysfunction as a downstream event of TSC1 or 
TSC2 mutations is important and might lead to novel therapeutic targets. mTOR-
associated diseases therefore highlight the close ties of the autophagy pathway to 
other fundamental signalling cascades and thus provide an opportunity to 
investigate the role of dysregulated autophagy in neurodevelopmental diseases. 
 
AUTOPHAGY IN LYSOSOMAL STORAGE DISEASES 
Progressive accumulation of undigested macromolecules in lysosomes is the 
hallmark feature of lysosomal storage diseases, a group of nearly 60 different 
diseases caused by mutations in genes encoding for lysosomal enzymes or 
membrane proteins (Boustany, 2013, Platt, 2014). Not surprisingly, impaired 
lysosomal metabolism has many effects on upstream pathways that mediate cargo 
delivery to the lysosomes. Recent studies have documented impaired autophagy in 
patient samples and disease models of many different lysosomal storage diseases 
(Lieberman et al., 2012, Ebrahimi-Fakhari et al., 2014). These deficits in autophagy 
are likely independent and significant contributors to neurodegeneration and other 
neuronal and non-neuronal disease manifestations, as convincingly illustrated in 
Niemann-Pick disease Type C (NP-C) models, where a block in autophagic flux and 
an accumulation of autophagosomes secondary to impaired maturation has been 
documented (Elrick et al., 2012, Maetzel et al., 2014, Sarkar et al., 2014). 
Interestingly, re-expression of NPC1, the protein mutated in NPC, restored 
autophagy deficits in NPC1-deficient cells, and pharmacological stimulation of 
autophagy had a cell-protective effect. The latter concept was recently confirmed in 
iPSC-derived hepatic and neuronal cells from NPC patients, where mTOR-
independent autophagy inducers, identified through a large-scale screening 
approach for small molecules, promoted cell viability (Maetzel et al., 2014). 
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Combining compounds that mobilize lysosomal cholesterol, such as 2-
hydroxypropyl-β-cyclodextrin (Vite et al., 2015) with inducers of autophagy is thus 
a promising novel therapeutic approach. Glycogen storage disease type II or Pompe 
disease, although primarily a severe myopathy, is another important case for the 
potential therapeutic role of autophagy. Genetic approaches that employ TFEB to 
enhance autophagic flux have shown great promise in proof-of-principle in vitro and 
in vivo studies (Spampanato et al., 2013). Future investigations for small molecules 
or effective genetic strategies that would render TFEB a clinically approachable 
target will prove or disprove the clinical utility of these findings for lysosomal storage 
diseases. 
 
UNIFYING FEATURES IN CONGENITAL DISORDERS OF AUTOPHAGY 
Major differences in the clinical manifestations of different congenital 
disorders of autophagy are obvious. This clinical heterogeneity may result from the 
fact that genes and proteins mutated in individual diseases map to different stages 
of the pathway and may lead to different degrees of residual autophagic activity. 
Clinical manifestations are also likely influenced by tissue-specific expression of 
autophagy proteins during and after development, differences in susceptibility of 
tissues to deficits in autophagy, a different degree of autophagic flux and metabolic 
activity in different cell types, and compensatory mechanisms or the existence of 
genetic or environmental modifiers. Identification and molecular delineation of novel 
congenital deficits of autophagy in humans will provide an understanding of these 
factors and will thus provide unique insights into the role of autophagy in human 
development and disease. Despite a variable clinical expression, a few unifying 
features are appreciable in congenital disorders of autophagy (Box 1). This includes, 
for example, a clinical manifestation in multiple organ systems with predominant 
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involvement of the nervous system, an onset in childhood or adolescence, a 
progressive disease course with neurodegenerative features, and a “storage 
phenotype” (Box 1). An involvement of the long white matter tracts as seen, for 
example, with agenesis or progressive thinning of the corpus callosum is another 
intriguing common denominator. How disruption of neuronal autophagy affects 
higher brain functions remains an open question and has implications for complex 
disease manifestations such as intellectual disability or epilepsy.  
 
RESTORING DEFICITS IN AUTOPHAGY AS A THERAPEUTIC APPROACH 
Pharmacological approaches that modulate autophagy have received 
increasing attention as a potential therapy for a broad range of autophagy-
associated diseases (Table 2) (Ebrahimi-Fakhari et al., 2012, Rubinsztein et al., 
2012, Nixon, 2013). Many small molecule inducers of autophagy act through the 
mTOR pathway (for example rapamycin and rapalogs), but mTOR-independent 
regulators also exist (such as for example carbamazepine or lithium which signal 
through inositol 1,4,5-trisphosphate; Table 2). Target specificity is a tremendous 
challenge for drug development, and many available compounds have autophagy-
independent off-target effects. Not surprisingly, a number of known autophagy 
modulators are currently in clinical trials or in clinical use for indications other than 
autophagy induction. It is imperative to learn how these compounds affect 
autophagy and whether existing drugs with an extensive clinical safety profile could 
be readily employed to target autophagy. This concerns, for example, the use of the 
antiepileptic drug carbamazepine (Hidvegi et al., 2010, Maetzel et al., 2014) or 
lysosomotropic agents such as chloroquine (Amaravadi et al., 2011). Although the 
diseases discussed in this review are rare, the extent to which they might inform us 
about therapeutic target in the autophagy pathway is significant. Based on current 
evidence, enhancing residual autophagy function or bypassing molecular deficits 
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appear to be rational therapeutic approaches for congenital disorders of autophagy. 
The latter might be achieved by targeting the stage of the autophagy pathway that is 
specifically disrupted in each given disease. Understanding the biology of 
congenital disorders of autophagy will help to design these proposed stage-specific 
autophagy-targeted therapies.  
Induced pluripotent stem cells (iPSCs) have emerged as a valuable pre-
clinical model to study rare diseases, given that reliable animal models for these 
conditions are often not readily available. In addition, several protocols exist that 
enable differentiation into relevant cell types such as neuronal cells. These will be 
instrumental for understanding disease phenotypes arising from different genetic 
mutations in individual patients and will provide a very useful platform for high 
throughput screening approaches that aim to identify molecules that restore 
autophagy function in a given disease. Recent studies have described the 
generation of human iPSC lines from patients with a range of inherited diseases 
(Park et al., 2008, Ebert et al., 2009, Lee et al., 2009, Marchetto et al., 2010) and 
proof-of-principle screening studies for modulators of autophagy using iPSC are 
emerging (Maetzel et al., 2014).  
 The transition from cellular and mouse models to humans will contest the 
potential for harnessing autophagy-based therapies. To translate potential targets 
into therapies, a challenge that will have to be overcome is the development of in 
vivo biomarkers to detect changes in autophagy in response to therapeutics or 
disease progression. This will be most effective when stage-specific methods or 
surrogate biomarkers become available to confirm target engagement, which will be 
essential to interpret outcomes in clinical trials. As with most congenital childhood-
onset diseases with a clear neurodevelopmental phenotype, another concern is the 
optimal timing to start treatment. Along the same lines, it remains to be seen 
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whether existing lesions, such as for example iron storage in the basal ganglia of 
BPAN patients, are reversible by correcting autophagy deficits.  
 
CONCLUSIONS 
Genetic disruption of the autophagy-lysosomal pathway, a fundamental metabolic 
pathway, results in a new and diverse group of multisystem diseases. We therefore 
argue that based on their shared genetic and molecular characteristics, these 
should be collectively termed congenital disorders of autophagy, a novel subclass 
within the field of inborn errors of metabolism. In the past two years alone, next-
generation sequencing technologies have allowed for the identification of a number 
of pathogenic mutations in core autophagy genes and will likely continue to reveal 
novel single gene disorders of this crucial cellular pathway. Bridging the gap 
between the identification of causative genes to the delineation of molecular disease 
mechanisms is an upcoming challenge. Development of disease models, such as 
those generated through iPSC technology, will allow us to gain insights into 
potential therapeutic targets and will yield novel therapies. Insights into congenital 
diseases of autophagy may be important to a wide spectrum of more common 
sporadic diseases with defective autophagy. 
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FIGURE LEGENDS 
Figure 1. The Three Main Subtypes Of Autophagy And Their Implications For 
Multiple Tissues And Organ Systems 
Autophagy mainly comprises of three subtypes: microautophagy, chaperone-
mediated autophagy and macroautophagy. These are distinguished based on the 
route and mechanism of cargo delivery to lysosomes, the final degrading organelles. 
Research over the last decades has elucidated a number of cell and tissue-specific 
functions that depend on or are critically influenced by autophagy. These functions 
are present in many organ systems, including the nervous system. The variety of 
functions of autophagy in different organ systems under physiological conditions is 
emphasized by the broad clinical manifestations in congenital disorders of 
autophagy, which manifest as multisystem diseases with prominent CNS pathology. 
Abbreviations: CMA (chaperone-mediated autophagy). 
 
Figure 2. Macroautophagy – An Overview Of The Molecular Pathway And 
Mutations Associated With Congenital Disorders Of Autophagy 
Macroautophagy is a step-wise process resulting in the formation of double-
membrane-bound autophagic vesicles that engulf their cargo before fusing with 
lysosomes. The principle stages of macroautophagy include: (I) initiation, (II) 
nucleation of an isolation membrane (also called phagophore), (III) elongation of 
evolving autophagic vesicles, (IV) engulfment of cargo and closure of the 
autophagosomal membrane, (V) autophagosome maturation, (VI) fusion with late 
endosomes or lysosomes, and finally (VII) degradation of cargo through lysosomal 
hydrolases. The last step yields basic metabolites that are then recycled. Mutations 
in congenital disorders of autophagy and single gene disorders associated with 
deficits in the regulation of autophagy impair different stages of the pathway. 
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Through interfering with the Beclin1 complex, hereditary spastic paraplegia-
associated recessive mutations in ZFYVE26 (SPG15) impair early stages such as the 
formation of the isolation membrane. Mutations in TECPR2 (SPG49) were recently 
shown to be critically involved in maintaining endoplasmic reticulum exit sites that 
may serve as scaffolds for the formation of early autophagosome intermediates. X-
linked WDR45 mutations cause beta-propeller protein-associated 
neurodegeneration (BPAN) and have been found to potentially interfere with the 
elongation of nascent autophagic vesicles. Autosomal-recessive EPG5 mutations in 
Vici syndrome as well as SNX14 mutations in SNX14-associated autosomal-
recessive cerebellar ataxia and intellectual disability syndrome impact the late 
stages of the autophagy pathway through impairing autophagosome-lysosome 
fusion. Mutations in SPG11 (SPG11) lead to a defect in autophagic lysosome 
reformation. Autophagy-associated diseases also affect different stages of 
autophagy regulation. An example for mTOR-associated neurodevelopmental 
diseases, loss of function mutations in TSC1 or TSC2 in tuberous sclerosis complex 
lead to constitutive activation of mTORC1 and thus block autophagic flux at multiple 
stages. Locating the defect to the late stages of the pathway, lysosomal storage 
diseases impact lysosomal metabolism and thus block upstream steps in the 
autophagy pathway. Impaired crosstalk between the lysosomal pathway and 
autophagosome biogenesis might also impact the coordinated regulation of both 
compartments. Abbreviations: AR-CAID (autosomal-recessive ataxia and intellectual 
disability syndrome); BPAN (beta-propeller protein-associated neurodegeneration); 
HSP (hereditary spastic paraplegia); LSD (lysosomal storage disease); TSC 
(tuberous sclerosis complex). 
 
Figure 3. Vici Syndrome – A Multisystem Disease 
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Mutations in the autophagy gene EPG5 cause Vici syndrome, a paradigm for 
multisystem diseases associated with defective autophagy. The eight cardinal 
features of Vici syndrome consist of agenesis of the corpus callosum, acquired 
microcephaly, bilateral cataracts, hypertrophic or dilated cardiomyopathy, combined 
immunodeficiency, and skin, hair or retinal hypopigmentation, failure to thrive and 
profound developmental delay. CNS manifestations are manifold and include 
congenital brain malformations such as agenesis of the corpus callosum with 
colpocephaly, cerebellar hypoplasia, hypoplasia/atrophy of the brain stem, 
abnormalities of the septum pellucidum, opercular hypoplasia and probably age-
dependent abnormal T2 signal in the thalami. Dysgenesis of the falx, non-
lissencephalic cortical dysplasia, polymicrogyria of the cerebral hemispheres, or 
bilateral schizencephaly have also been reported in a few individuals. Delayed 
myelination and diffuse white matter atrophy are commonly reported. Pointing to the 
potential presence of a neurodegenerative phenotype in addition to prominent 
deficits in brain development, dilated ventricles, Purkinje cell loss, and diffuse 
cerebral atrophy have been described in a subset of patients. 
 
Figure 4. Beta-Propeller Protein-Associated Neurodegeneration (BPAN) – 
Natural History Of A Biphasic Disease 
Patients with WDR45-mutation associated BPAN commonly present with a distinct 
biphasic clinical course. Initial manifestations in infancy or early childhood consist of 
global developmental delay, intellectual disability, and seizures, which tend to 
progress in the later stages of the disease. Cerebellar ataxia, spasticity, Rett-like 
hand stereotypies, and autistic features have also been reported in a subset of 
patients. The disease advances in adolescence or early adulthood when dystonia, 
Parkinsonism, and progressive cognitive decline become prominent. Other 
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manifestations often include bladder and bowel incontinence, disordered sleep, and 
visual and auditory deficits.
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Table 1. Congenital disorders of autophagy 
Disease (# OMIM) Gene Affected stage of the 
autophagy pathway 
Neurological Manifestations 
Vici syndrome 
(#242840) 
EPG5 Late stages: 
• Autophagosome-
lysosome fusion 
• Proteolysis within 
autolysosomes 
• Agenesis of the corpus callosum 
and other congenital brain 
malformations 
• Delayed myelination and white 
matter atrophy 
• Acquired microcephaly and 
dysmorphic features 
• Developmental delay / 
developmental regression 
• Failure to thrive 
• Muscular hypotonia 
• Seizures 
• Sensorineural deafness 
Beta-propeller 
protein-associated 
neurodegeneration 
(#300894) 
WDR45 Early stages: 
• Autophagosome 
elongation 
Childhood: 
• Developmental delay / 
intellectual disability 
• Seizures 
• Spastic paraplegia 
• Rett-like stereotypies 
• Autistic features 
Adolescence: 
• Progressive dementia 
• Parkinsonism, dystonia 
• Optic nerve atrophy 
• Sensorineural hearing loss 
• Bladder and bowel incontinence 
• Sleep disorder 
SNX14-associated 
autosomal-
recessive 
cerebellar ataxia 
SNX14 Late stage: 
• Autophagosome-
lysosome fusion 
(probably) 
• Progressive cerebellar atrophy 
and ataxia 
• Developmental delay / 
intellectual disability 
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and intellectual 
disability 
syndrome 
(#616105) 
• Muscular hypotonia 
• Seizures 
• Autistic features 
• Storage disease phenotype 
Hereditary spastic 
paraplegia - 
SPG11 
(#604360)  
& 
Hereditary spastic 
paraplegia - 
SPG15 
(#270700) 
SPG11 
& 
ZFYVE
26 
SPG11:  
Late stage: 
• Lysosome 
reformation / 
biogenesis 
 
SPG15: 
Early, middle and late 
stages: 
• Autophagosome 
initiation / 
nucleation 
• Autophagosome 
maturation 
• Autophagosome-
lysosome fusion 
• Lysosome 
reformation / 
biogenesis 
• Progressive spasticity and 
weakness of the lower limbs 
• Developmental delay / cognitive 
decline 
• Thinning of the corpus callosum 
• Axonal, motor, or sensorimotor 
peripheral neuropathy 
• Pseudobulbar involvement with 
dysarthria and dysphagia 
Less common: 
• Retinal degeneration (Kjellin 
syndrome) 
• Cerebellar ataxia 
• Parkinsonism 
Hereditary spastic 
paraplegia -
SPG49 
(#615031) 
TECPR
2 
Early stages: 
• Autophagosome 
nucleation 
(probably) 
• Progressive spasticity and 
weakness of the lower limbs 
• Developmental delay / cognitive 
decline 
• Muscular hypotonia 
• Microcephaly and dysmorphic 
features 
• Cerebellar dysfunction 
• Central apnoea 
• Seizures 
• Thinning of the corpus callosum  
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Table 2. Modulators Of Autophagy In Neuronal Disease Models 
Compound Proposed Target and Mechanism Model System & Selected 
References 
Bafilomycin 
A1 
Autophagy Inhibition 
• Inhibition of the vacuolar-type 
ATPase 
• Disrupts lysosomal acidification and 
prevents autophagosome-lysosome 
fusion 
Neuronal cell models (Shacka et 
al., 2006, Bains et al., 2009); 
mouse models (Ebrahimi-Fakhari 
et al., 2011, Klucken et al., 2012) 
Carbamaze
pine 
Autophagy induction 
• Voltage-gated Na2+ channel inhibitor 
• Lowers inositol and inositol-1,4,5-
triphosphate levels 
Neuronal cell models (Williams et 
al., 2008, Xiong et al., 2011); 
iPSC-derived neuronal cells 
(Maetzel et al., 2014); mouse 
models (Wang et al., 2012a, Li et 
al., 2013) 
(Hydroxy-) 
Chloroquine 
Autophagy inhibition 
• Disrupts lysosomal acidification and 
prevents autophagosome-lysosome 
fusion 
Neuronal cell models (Boland et 
al., 2010); mouse models 
(Ebrahimi-Fakhari et al., 2011, 
Vodicka et al., 2014) 
Clonidine Autophagy induction 
• Imidazole receptor agonist 
• Lowers cAMP levels 
Neuronal cell model; Drosophila 
melanogaster; zebrafish (Williams 
et al., 2008) 
Latrepirdine Autophagy induction 
• mTORC1 inhibition 
Neuronal cell model; mouse 
models (Steele et al., 2013a, 
Steele et al., 2013b) 
Lithium Autophagy induction 
• Inositol monophosphatase inhibitor 
• Lowers inositol and inositol-1,4,5-
triphosphate levels 
Neuronal cell models (Sarkar et 
al., 2005, Chang et al., 2011); 
mouse models (Sarkar et al., 
2005, Fornai et al., 2008, 
Shimada et al., 2012, Duarte-
Silva et al., 2014) 
Nilotinib Autophagy induction 
• Abl tyrosine kinase inhibitor 
• Activates AMPK 
Mouse models (Hebron et al., 
2013, Lonskaya et al., 2014) 
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Rapamycin 
and 
rapalogs 
Autophagy induction 
• mTORC1 inhibition 
Neuronal cell models (Webb et 
al., 2003, Pan et al., 2008b, 
Williams et al., 2008); mouse 
models (Ravikumar et al., 2004, 
Menzies et al., 2010, Majumder 
et al., 2011, Cortes et al., 2012, 
Viscomi et al., 2012, Jiang et al., 
2014) 
Resveratrol Autophagy induction 
• Sirtuin-1 activation 
• Activates AMPK  
Neuronal cell model (Vingtdeux 
et al., 2010); mouse model 
(Vingtdeux et al., 2010, Shu et al., 
2015) 
Rilmenidine Autophagy induction 
• Imidazole receptor agonist 
• Lowers cAMP levels 
Neuronal cell model (Williams et 
al., 2008, Rose et al., 2010); 
mouse model (Rose et al., 2010) 
SMER28 
and other 
SMER 
Autophagy induction 
• Unknown mechanism, likely mTOR-
independent 
Neuronal cell model (Tian et al., 
2011); Drosophila melanogaster 
(Sarkar et al., 2007b) 
Trehalose Autophagy induction  
• Chemical chaperone 
Neuronal cell model (Sarkar et 
al., 2007a); mouse models 
(Rodriguez-Navarro et al., 2010, 
Schaeffer et al., 2012, Castillo et 
al., 2013, Zhang et al., 2014, He 
et al., 2015, Li et al., 2015) 
Valproate Autophagy induction 
• Myo-inositol-3-phosphate synthase 
inhibitor 
• Lowers inositol and inositol-1,4,5-
triphosphate levels 
Neuronal cell model; Drosophila 
melanogaster (Williams et al., 
2008) 
Verapamil 
(and other 
Ca2+-
channel 
blockers) 
Autophagy induction 
• L-type Ca2+-channel antagonist  
• Lowers intracellular calcium levels 
Neuronal cell model; Drosophila 
melanogaster; zebrafish (Williams 
et al., 2008) 
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Box 1. Unifying clinical characteristics of congenital disorders of autophagy 
• Disease onset in early childhood / adolescence 
• Prominent nervous system involvement  
• Multiple brain regions involved 
• Long white-matter tracts (corpus callosum and cortico-spinal tract) and 
the cerebellum (Purkinje cells) are often affected 
• Neurodegenerative phenotype with developmental regression and 
cognitive decline 
• Storage disease phenotype 
• Delayed development / intellectual disability, muscular hypotonia, 
seizures and movement disorders are common 
• Often multisystem disease with additional non-neuronal manifestations 
(including myopathy and ophthalmic manifestations) 
• Progressive disease course, often fatal 
 
